- Home
- LSF vs OPTN Comparison
LSF vs OPTN Comparison
Compare LSF & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- OPTN
- Stock Information
- Founded
- LSF 2015
- OPTN 2010
- Country
- LSF United States
- OPTN United States
- Employees
- LSF N/A
- OPTN N/A
- Industry
- LSF Packaged Foods
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- OPTN Health Care
- Exchange
- LSF Nasdaq
- OPTN Nasdaq
- Market Cap
- LSF 55.5M
- OPTN 55.4M
- IPO Year
- LSF 2020
- OPTN 2017
- Fundamental
- Price
- LSF $5.27
- OPTN $9.17
- Analyst Decision
- LSF Strong Buy
- OPTN Hold
- Analyst Count
- LSF 2
- OPTN 3
- Target Price
- LSF $7.75
- OPTN $9.00
- AVG Volume (30 Days)
- LSF 73.0K
- OPTN 141.6K
- Earning Date
- LSF 05-07-2025
- OPTN 05-13-2025
- Dividend Yield
- LSF N/A
- OPTN N/A
- EPS Growth
- LSF N/A
- OPTN N/A
- EPS
- LSF N/A
- OPTN N/A
- Revenue
- LSF $43,295,137.00
- OPTN $78,226,000.00
- Revenue This Year
- LSF $22.58
- OPTN $30.49
- Revenue Next Year
- LSF $20.06
- OPTN $13.51
- P/E Ratio
- LSF N/A
- OPTN N/A
- Revenue Growth
- LSF 26.50
- OPTN 10.20
- 52 Week Low
- LSF $1.90
- OPTN $4.82
- 52 Week High
- LSF $10.90
- OPTN $20.03
- Technical
- Relative Strength Index (RSI)
- LSF 44.60
- OPTN 76.77
- Support Level
- LSF $5.00
- OPTN $8.75
- Resistance Level
- LSF $5.51
- OPTN $9.28
- Average True Range (ATR)
- LSF 0.47
- OPTN 0.14
- MACD
- LSF 0.01
- OPTN -0.11
- Stochastic Oscillator
- LSF 44.96
- OPTN 79.25
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.